Comparative cellular catabolism and retention of astatine-, bismuth-, and lead-radiolabeled internalizing monoclonal antibody
Z Yao, K Garmestani, KJ Wong, LS Park… - Journal of Nuclear …, 2001 - Soc Nuclear Med
Monoclonal antibodies (mAbs) labeled with α-emitting radionuclides such as 211At, 212Bi,
213Bi, and 212Pb (which decays by β-emission to its α-emitting daughter, 212Bi) are being …
213Bi, and 212Pb (which decays by β-emission to its α-emitting daughter, 212Bi) are being …
Long-lived alpha emitters in radioimmunotherapy: the mischievous progeny
G Sgouros - Cancer Biotherapy and Radiopharmaceuticals, 2000 - liebertpub.com
The potential of alpha-particle emitters in radioimmunotherapy has been recognized since
the 80's. 1, 2 It is only recently, however, that such radionuclides have entered clinical trials …
the 80's. 1, 2 It is only recently, however, that such radionuclides have entered clinical trials …
Radioimmunotherapy with alpha-emitting nuclides
This review discusses the application of alpha particle-emitting radionuclides in targeted
radioimmunotherapy. It will outline the production and chemistry of astatine-211, bismuth …
radioimmunotherapy. It will outline the production and chemistry of astatine-211, bismuth …
Biodistributions, myelosuppression, and toxicities in mice treated with an anti-CD45 antibody labeled with the α-emitting radionuclides bismuth-213 or astatine-211
H Nakamae, DS Wilbur, DK Hamlin, MS Thakar… - Cancer research, 2009 - AACR
We previously investigated the potential of targeted radiotherapy using a bismuth-213
(213Bi)–labeled anti-CD45 antibody to replace total body irradiation as conditioning for …
(213Bi)–labeled anti-CD45 antibody to replace total body irradiation as conditioning for …
[HTML][HTML] Preparation of 212Pb-labeled monoclonal antibody using a novel 224Ra-based generator solution
S Westrøm, R Generalov, TB Bønsdorff… - Nuclear medicine and …, 2017 - Elsevier
Introduction Alpha-emitting radionuclides have gained considerable attention as payloads
for cancer targeting molecules due to their high cytotoxicity. One attractive radionuclide for …
for cancer targeting molecules due to their high cytotoxicity. One attractive radionuclide for …
Methodology for labeling proteins and peptides with lead-212 (212Pb)
KE Baidoo, DE Milenic, MW Brechbiel - Nuclear medicine and biology, 2013 - Elsevier
INTRODUCTION: Alpha particles possess an exquisite degree of cytotoxicity when
employed for targeted α-particle therapy (TAT) or radioimmunotherapy (RIT). 212Pb, which …
employed for targeted α-particle therapy (TAT) or radioimmunotherapy (RIT). 212Pb, which …
Comparative Tissue Distribution in Mice of the α-Emitter 211At and 131I as Labels of a Monoclonal Antibody and F(ab′)2 Fragment
PK Garg, CL Harrison, MR Zalutsky - Cancer research, 1990 - AACR
Because it decays by the emission of short-range, high-energy α-particles, the radiohalogen
211At might be a particularly useful nuclide for some types of radioimmunotherapy …
211At might be a particularly useful nuclide for some types of radioimmunotherapy …
The promise of targeted α-particle therapy
DA Mulford, DA Scheinberg… - Journal of Nuclear …, 2005 - Soc Nuclear Med
The use of monoclonal antibodies to deliver radioisotopes directly to tumor cells has
become a promising strategy to enhance the antitumor effects of native antibodies. Since the …
become a promising strategy to enhance the antitumor effects of native antibodies. Since the …
[PDF][PDF] Pharmacokinetics and dosimetry of an α-particle emitter labeled antibody: 213Bi-HuM195 (anti-CD33) in patients with leukemia
G Sgouros, ÅM Ballangrud, JG Jurcic… - Journal of Nuclear …, 1999 - Soc Nuclear Med
Data from nine patients with leukemia participating in a phase I activity-escalation study of
HuM195, labeled with the a-particle emitter 213Bi (half-life= 45.6 min), were used to …
HuM195, labeled with the a-particle emitter 213Bi (half-life= 45.6 min), were used to …
Alpha-particle radioimmunotherapy with astatine-211 and bismuth-213
G Lucignani - European journal of nuclear medicine and molecular …, 2008 - Springer
Radioimmunotherapy (RIT) with β-emitting radionuclides is an established part of the
treatment of some haematological malignancies. Over the past two decades, new αemitters …
treatment of some haematological malignancies. Over the past two decades, new αemitters …